Hot Life Sciences Stocks To Invest In 2015: H&Q Life Sciences Investors (HQL)
H&Q Life Sciences Investors (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in life science companies (including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies) agriculture and environmental management. The Fund invests primarily in securities of public and private companies.
The Fund may invest in venture capital and other restricted securities if these securities would comprise 40% or less of net assets. The Fund may purchase and sell (or write) put or call options on any security in which it is permitted to invest. It may purchase and sell (write) options on stock indices (index options). H&Q Life Sciences Investors investment advisor is Hambrecht & Quist Capital Management, LLC.Advisors' Opinion:
- [By Nate Pile]
This recommended fundHambrecht & Quist Life Sciences Fund (HQL)was also our top pick last year, and the fund rose 44% in 2013.
In addition to rising in value, the fund has a dividend policy of paying out 2% of its net asset value of each quarter.
- [By Harry Domash, Publisher, DividendDetective and Winning Investing]
Harry Domash: Yeah, in fact, H&Q Life Sciences, ticker (HQL), is actually a closed-end fund, but it invests entirely in biotech and pharmaceutical companies, and if you look around the world, the investing stocks right now—besides the social media stocks—that's really the one area that has had a lot of recent growth and we expect that to continue.
I think the closed-end fund, and we'll get into that maybe a little bit later, but closed-end funds are a good way to cover it, when you're talking about a sector like that.
Johnson & Johnson is an ! interesting case, because, as you know, Johnson & Johnson is a big company that invests, and that owns a lot of different companies itself in the medical field.
You know, it owns hundreds of operating companies and it's primarily in the pharmaceuticals, and medical devices, and in consumer products, but Johnson & Johnson was a mismanaged company for a while and they were really underperforming their peers.
In fact, some of their factories were closed, their pharmaceutical production factories were forcibly closed by the government because they didn't meet standards, but they were taken over by a new CEO a few years ago, two or three years ago, and now things are improving, so Johnson & Johnson is kind of coming from down and out to being a leading company again.
They've got a lot of products, cancer-type products, and things on the pipeline and it just seems like things are going very well so we have hopes that Johnson & Johnson has reported the last two quarters are the first ones that have really been decent, they really showed growth, and then we expect that to accelerate so we're pretty hot on Johnson & Johnson now.
Steve Halpern: One particularly interesting portfolio that you maintain that I haven't seen anywhere else is based on closed-end funds that pay monthly dividends&mdash
source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-life-sciences-stocks-to-invest-in-2015-2.html